Explore the detailed record of transactions filed by AJT FINANCIERE SAS, Président de SAS AJT FINANCIERE et dirigeant lié à BIOSYNEX. Insider active across 1 companies, notably BIOSYNEX. In total, 1 filings have been recorded. Total volume traded: €10k. The latest transaction was filed on 28 January 2025 — Cession. Regulator: AMF. The full history is openly available.
1 of 1 declaration
AJT FINANCIERE SAS is a holding and governance-related vehicle closely linked to BIOSYNEX. In BIOSYNEX’s published financial documents, AJT FINANCIERE is identified as the company represented by Thomas LAMY, who serves as its managing officer and president, and who for many years held senior leadership roles within BIOSYNEX, including Deputy Chief Executive Officer and board member until January 13, 2025. This indicates that the entity has played an active role in the group’s governance and strategic continuity rather than being a passive shareholder. Thomas LAMY’s career is deeply embedded in the BIOSYNEX ecosystem, a French laboratory specialized in the design, manufacturing, and distribution of rapid diagnostic tests in France and internationally. Annual reports and governance filings show that he carried both executive and board responsibilities while also leading AJT FINANCIERE, a company based in Strasbourg. This combination of operating leadership and shareholder/holding-company involvement is common in growth-oriented listed groups, where stable ownership and managerial continuity are important strategic assets. From an achievement perspective, the recent period has been shaped by BIOSYNEX’s restructuring efforts and by the monitoring of regulated agreements between the listed company and AJT FINANCIERE, including fees disclosed in the statutory auditors’ special report for 2024. This suggests involvement in advisory, oversight, or strategic support functions serving the group. Through AJT FINANCIERE, Thomas LAMY appears to embody a long-term governance profile that combines financial expertise, close proximity to the leadership team, and a strong understanding of BIOSYNEX’s industrial, commercial, and capital-structure priorities.